U.S. Markets closed

GW Pharmaceuticals plc (GWPH)


NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
114.92+0.43 (+0.38%)
At close: 4:00PM EDT
People also watch
INSYCARACANNTRTCTWMJF

GW Pharmaceuticals plc

Sovereign House
Vision Park
Cambridge CB24 9BZ
United Kingdom
44 1223 266 800
http://www.gwpharm.com

SectorHealthcare
IndustryDrug Manufacturers - Major
Full Time Employees508

Key Executives

NameTitlePayExercisedAge
Dr. Geoffrey W. Guy BSc, MB BS, MRCS Eng, LRCP, LMSSA. Dip Pharm MedFounder and Exec. ChairmanN/AN/A63
Mr. Justin D. Gover BSc, MBAChief Exec. Officer and Exec. DirectorN/AN/A46
Mr. Christopher John Tovey BScChief Operating OfficerN/AN/A52
Mr. Adam David George BSc, ACAManaging Director of UK and Sec.N/AN/A47
Mr. Julian S. GangolliPres of North America459.45kN/A59
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. It operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The company markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. It is also developing Sativex in Phase II trials in neuropathic pain. In addition, the company’s product pipeline includes Epidiolex, which is in Phase III clinical development for the treatment of dravet syndrome, lennox-gastaut syndrome, tuberous sclerosis complex, and infantile spasms, as well as other product candidates in Phase I and II clinical development for the treatment of glioma, adult epilepsy, and schizophrenia. It primarily operates Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.

Corporate Governance

GW Pharmaceuticals plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.